Cardiac amyloidosis, characterized by progressive restrictive cardiomyopathy, presents unusual diagnostic challenges. Conventional cardiac scintigraphy has shown limited utility in the quantification of disease burden and serial follow-up of cardiac amyloidosis. The advent of specialized positron emission tomography with specific amyloid-binding radiotracers has the potential to change currently employed diagnostic algorithms for the imaging of cardiac amyloidosis. This review aims to discuss the diagnostic utility of amyloid-binding radiotracers, including Pittsburg compound B, florbetapir, florbetapan, and sodium fluoride. These tracers have promising potential for the early detection of the particular type of cardiac amyloidosis, pursuing relevant medical intervention, assessing amyloid burden, monitoring treatment response, and overall prognostication.

以进行性限制性心肌病为特征的心脏淀粉样变性具有不同寻常的诊断挑战。常规心脏闪烁显像在疾病负担的量化和心脏淀粉样变性的系列随访中显示出有限的效用。具有特定淀粉样蛋白结合放射性示踪剂的专业正电子发射断层扫描的出现有可能改变目前用于心脏淀粉样变性成像的诊断算法。本综述旨在讨论淀粉样蛋白结合放射性示踪剂的诊断效用，包括匹兹堡化合物 B、florbetapir、florbetapan 和氟化钠。这些示踪剂在早期检测特定类型的心脏淀粉样变性、进行相关医疗干预、评估淀粉样蛋白负荷、监测治疗反应、